73 related articles for article (PubMed ID: 31649118)
1. Clinical value of the expression levels of tumor protein D52 and miR-133a on prognosis assessment of pancreatic cancer surgery.
Wang ZY; Liu RH; Meng Y; Li JC
Pak J Med Sci; 2024; 40(4):723-729. PubMed ID: 38544991
[TBL] [Abstract][Full Text] [Related]
2. Tumor protein D52 (TPD52) affects cancer cell metabolism by negatively regulating AMPK.
Chen Y; Peng C; Tan W; Yu J; Zayas J; Peng Y; Lou Z; Pei H; Wang L
Cancer Med; 2023 Jan; 12(1):488-499. PubMed ID: 35666017
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-449a Inhibits Tumor Metastasis through AKT/ERK1/2 Inactivation by Targeting Steroid Receptor Coactivator (SRC) in Endometrial Cancer.
Hu Y; Wu AY; Xu C; Song KQ; Wang WJ; Yin X; Di W; Hong ZB; Qiu LH
J Cancer; 2019; 10(2):547-555. PubMed ID: 30719151
[TBL] [Abstract][Full Text] [Related]
4. Preclinical support for tumor protein D52 as a cancer vaccine antigen.
Bright RK
Hum Vaccin Immunother; 2023 Dec; 19(3):2273699. PubMed ID: 37904517
[TBL] [Abstract][Full Text] [Related]
5. Cross talk of tumor protein D52 (TPD52) with KLF9, PKCε, and MicroRNA 223 in ovarian cancer.
Khan K; Zafar S; Badshah Y; Ashraf NM; Rafiq M; Danish L; Shabbir M; Trembley JH; Afsar T; Almajwal A; Razak S
J Ovarian Res; 2023 Oct; 16(1):202. PubMed ID: 37833790
[TBL] [Abstract][Full Text] [Related]
6. TPD52 is a prognostic biomarker and potential therapeutic target for ER+/PR+/HER2+ breast cancer.
Cheng X; Li Z; Jia X; Fan Z; He Q; Zhuang Z
Chin Clin Oncol; 2024 Jun; ():. PubMed ID: 38859601
[TBL] [Abstract][Full Text] [Related]
7. TPD52 is a Potential Prognostic Biomarker and Correlated with Immune Infiltration: A Pan-cancer Analysis.
Miao L; Jing L; Chen B; Zeng T; Chen Y
Curr Mol Med; 2023 Oct; ():. PubMed ID: 38178662
[TBL] [Abstract][Full Text] [Related]
8. Predicting 3D Structure, Cross Talks, and Prognostic Significance of
Safi S; Badshah Y; Shabbir M; Zahra K; Khan K; Dilshad E; Afsar T; Almajwal A; Alruwaili NW; Al-Disi D; Abulmeaty M; Razak S
Front Oncol; 2021; 11():797007. PubMed ID: 35047407
[TBL] [Abstract][Full Text] [Related]
9. miR-449a: A Promising Biomarker and Therapeutic Target in Cancer and Other Diseases.
Barati T; Mirzaei Z; Ebrahimi A; Shekari Khaniani M; Mansoori Derakhshan S
Cell Biochem Biophys; 2024 May; ():. PubMed ID: 38809350
[TBL] [Abstract][Full Text] [Related]
10. A High-Throughput Small Molecule Screen Identifies Ouabain as Synergistic with miR-34a in Killing Lung Cancer Cells.
Rupaimoole R; Yoon B; Zhang WC; Adams BD; Slack FJ
iScience; 2020 Feb; 23(2):100878. PubMed ID: 32062455
[TBL] [Abstract][Full Text] [Related]
11. Correction for Ielpo et al., GABAergic miR-34a regulates Dorsal Raphè inhibitory transmission in response to aversive, but not rewarding, stimuli.
Proc Natl Acad Sci U S A; 2023 Oct; 120(41):e2315642120. PubMed ID: 37796991
[No Abstract] [Full Text] [Related]
12. Star-PAP RNA Binding Landscape Reveals Novel Role of Star-PAP in mRNA Metabolism That Requires RBM10-RNA Association.
Koshre GR; Shaji F; Mohanan NK; Mohan N; Ali J; Laishram RS
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576144
[TBL] [Abstract][Full Text] [Related]
13. Star-PAP regulates tumor protein D52 through modulating miR-449a/34a in breast cancer.
Duan A; Kong L; An T; Zhou H; Yu C; Li Y
Biol Open; 2019 Nov; 8(11):. PubMed ID: 31649118
[TBL] [Abstract][Full Text] [Related]
14. Tumor-suppressive microRNA-34a inhibits breast cancer cell migration and invasion via targeting oncogenic TPD52.
Li G; Yao L; Zhang J; Li X; Dang S; Zeng K; Zhou Y; Gao F
Tumour Biol; 2016 Jun; 37(6):7481-91. PubMed ID: 26678891
[TBL] [Abstract][Full Text] [Related]
15. Star-PAP controls oncogene expression through primary miRNA 3'-end formation to regulate cellular proliferation and tumour formation.
Mohanan NK; Shaji F; Sudheesh AP; Bangalore Prabhashankar A; Sundaresan NR; Laishram RS
Biochim Biophys Acta Mol Basis Dis; 2024 Apr; 1870(4):167080. PubMed ID: 38364942
[TBL] [Abstract][Full Text] [Related]
16. Tumor protein D52 promotes breast cancer proliferation and migration via the long non-coding RNA NEAT1/microRNA-218-5p axis.
Ren J; Chen Y; Kong W; Li Y; Lu F
Ann Transl Med; 2021 Jun; 9(12):1008. PubMed ID: 34277808
[TBL] [Abstract][Full Text] [Related]
17. Expanding the Biotherapeutics Realm via miR-34a: "Potent Clever Little" Agent in Breast Cancer Therapy.
Mohammady M; Ghetmiri SI; Baharizade M; Morowvat MH; Torabi S
Curr Pharm Biotechnol; 2019; 20(8):665-673. PubMed ID: 31244419
[TBL] [Abstract][Full Text] [Related]
18. miR-449a: a potential therapeutic agent for cancer.
Yong-Ming H; Ai-Jun J; Xiao-Yue X; Jian-Wei L; Chen Y; Ye C
Anticancer Drugs; 2017 Nov; 28(10):1067-1078. PubMed ID: 29023247
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
